Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL PFS with1mL Pre-filled Syringe in Adult Participants With Autoimmune Disease

Recruiting

Phase 2

Sponsor:

Novartis Pharmaceuticals

Code:

NCT06293365

Conditions

Sjögrens Disease

Systemic Lupus Erythematosus

Rheumatoid Arthritis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

VAY736 1ml PFS

VAY736 2 ml PFS

VAY736 2ml AI

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information